Getting latest data loading
Home / Morning Report / Morning Report

This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.

Morning Report - 30 September 2019

Yesterday’s UK 100 Leaders Price (p) % Chg
PERSIMMON PLC 2,175.0 5.2%
KINGFISHER PLC 208.9 3.6%
SMURFIT KAPPA GROUP PLC 2,452.0 3.6%
3I GROUP PLC 1,184.5 3.4%
NEXT PLC 6,216.0 3.1%
Yesterday’s UK 100 Laggards Price (p) % Chg
FRESNILLO PLC 703.0 -3.7%
POLYMETAL INTERNATIONAL PLC 1148.0 -2.5%
IMPERIAL BRANDS PLC 1774.6 -1.3%
ADMIRAL GROUP PLC 2084.0 -0.8%
PEARSON PLC 734.4 -0.8%
Major World Indices Price % Chg 1 Year
UK 100 INDEX 7,426 1.0% -1.6%
DOW JONES INDUS. AVG 26,820 -0.3% 1.7%
DAX INDEX 12,381 0.8% -0.4%
NIKKEI 225 21,879 -0.8% -8.1%
S&P/ASX 200 INDEX 6,716 0.6% 8.7%
Commodities Units Price % Chg
WTI Crude Oil (Nymex) USD/bbl. 55.85 -0.11%
Brent Crude (ICE) USD/bbl. 61.71 -0.32%
Gold Spot USD/t oz. 1,490 -0.5%
Copper (Comex) USd/lb. 261 0.6%
UK 100 called to open -5 points at 7422

UK 100 : 4 hours, 26 days

Click graph to enlarge

Markets Overview:

UK Index called to open -5 Points at 7422 this morning; Chinese data overnight expanded at its fastest pace for 19 months, however China edged lower overnight ahead of a long holiday, as sentiment was dented by the US considering to delist Chinese companies from US stock exchanges. Oil is flat over the weekend and Gold -0.5% heading into the new week.

 

In corporate news this morning:

AstraZeneca has announced that its drug Tagrisso is the only 1st-line treatment for EGFR-mutated non-small cell lung cancer to deliver a median overall survival of more than three years

 

Ferrexpo rejects claims that it’s CEO Kostyantin Zhevago has been served with a notice of suspicion regarding an investigation in Ukraine relating to one of the businesses he owned until 2015.

 

GSK presents new data showing promising anti-tumour activity with GSK3359609, an ICOS receptor agonist, in combination with pembrolizumab in head and neck squamous cell carcinoma.

 

GSK also announced Phase 3 PRIMA trial of Zejula (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardless of biomarker status, when given as monotherapy in women with first-line platinum responsive advanced ovarian cancer.

IQE announces the successful device and module qualification for VCSEL epi-wafers for a major Asian OEM.

 

Source: Bloomberg, FT, Reuters, DJ Newswires, AlphaTerminal

 

Upgrades/Downgrades:

Pennon Group Upgraded to a buy by Deutsche Bank (Bloomberg: 7 Buys / 4 Holds / 2 Sells)

 

Whitbread Downgraded to Equal Weight by Barclays (Bloomberg: 3 Buys / 15 Holds / 8 Sells)

 

 

 

In Focus Today:

 

Chinese Caixin Manufacturing PMI

 

UK GDP Q2 QoQ

 

German Consumer Price Index

 

Companies reporting today:

 

GlaxoSmithKline

 

 

Companies reporting Tomorrow:

 

Greggs, Ferguson

 

 

Companies reporting this week:

 

Tesco, Wizz Air, Ted Baker

 

(Full list available on Week in advance)

 

This Week's Ex-Dividends:

 

DS Smith - 3.2%

 

Taylor Wimpey - 2.4%

 

WPP - 2.3%

 

British American Tobacco - 1.8%

 

Hays - 5.6%

 

(Full list available on Week in advance)

For any help you may require placing trades or in terms of market information, put a call in to our trading floor – it’s all part of the service.


Back to Top

This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.


Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance.

Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when spread betting and/or trading CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
.